Strata Intangible Assets from 2010 to 2026
| SRTA Stock | 4.69 0.13 2.70% |
Intangible Assets | First Reported 2020-09-30 | Previous Quarter 13.6 M | Current Value 49.8 M | Quarterly Volatility 16.6 M |
Check Strata Critical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Strata Critical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.2 M, Selling General Administrative of 53 M or Selling And Marketing Expenses of 6.7 M, as well as many indicators such as Price To Sales Ratio of 1.45, Dividend Yield of 0.0 or PTB Ratio of 1.62. Strata financial statements analysis is a perfect complement when working with Strata Critical Valuation or Volatility modules.
Strata | Intangible Assets | Build AI portfolio with Strata Stock |
Analyzing Strata Critical's Intangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Intangible Assets has evolved provides context for assessing Strata Critical's current valuation and future prospects.
Latest Strata Critical's Intangible Assets Growth Pattern
Below is the plot of the Intangible Assets of Strata Critical Medical over the last few years. It is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. Strata Critical's Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Strata Critical's overall financial position and show how it may be relating to other accounts over time.
| Intangible Assets | 10 Years Trend |
|
Intangible Assets |
| Timeline |
Strata Intangible Assets Regression Statistics
| Arithmetic Mean | 8,807,645 | |
| Geometric Mean | 1,983,649 | |
| Coefficient Of Variation | 150.81 | |
| Mean Deviation | 10,708,364 | |
| Median | 533,000 | |
| Standard Deviation | 13,283,027 | |
| Sample Variance | 176.4T | |
| Range | 45.8M | |
| R-Value | 0.67 | |
| Mean Square Error | 103.2T | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | 1,767,691 | |
| Total Sum of Squares | 2823T |
Strata Intangible Assets History
About Strata Critical Financial Statements
Strata Critical stakeholders use historical fundamental indicators, such as Strata Critical's Intangible Assets, to determine how well the company is positioned to perform in the future. Although Strata Critical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Strata Critical's assets and liabilities are reflected in the revenues and expenses on Strata Critical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Strata Critical Medical. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Intangible Assets | 15.7 M | 23.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Strata Critical Medical is a strong investment it is important to analyze Strata Critical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Strata Critical's future performance. For an informed investment choice regarding Strata Stock, refer to the following important reports:Check out the analysis of Strata Critical Correlation against competitors. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Ground Transportation space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Strata Critical. If investors know Strata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Strata Critical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.24) | Revenue Per Share | Quarterly Revenue Growth 2.083 | Return On Assets | Return On Equity |
The market value of Strata Critical Medical is measured differently than its book value, which is the value of Strata that is recorded on the company's balance sheet. Investors also form their own opinion of Strata Critical's value that differs from its market value or its book value, called intrinsic value, which is Strata Critical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Strata Critical's market value can be influenced by many factors that don't directly affect Strata Critical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Strata Critical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Strata Critical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Strata Critical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.